Compare Applovin Corporation (APP) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applovin Corporation vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Applovin Corporation trades at $507.11 (market cap $170.31B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $294.72 (market cap $7.94B). The key difference: Applovin Corporation is far larger — about 21.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.
| APP | BIO | |
|---|---|---|
Market Cap | $170.31B | $7.94B |
Sector | Technology | Health |
52-Week High | $733.60 | $339.75 |
52-Week Low | $335.10 | $241.71 |
Enterprise Value | $171.07B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AppLovin trades at $506.98, down 2.58% today, with a bullish technical setup near pivot point support at $504. The company shows exceptional fundamentals with 59% revenue growth in Q1 2026 and net margins exceeding 64%. Analyst consensus remains strongly bullish with an $644.09 price target, supported by expanding e-commerce advertising share and AI-driven platform growth noted in recent Jefferies research.
The outlook remains positive given consistent earnings beats and projected revenue growth to $6.2B in 2026. Primary risks include premium valuation multiples (P/E 44.09) and competitive pressure in mobile advertising. The stock offers growth exposure but requires monitoring of execution against high expectations.
BIO trades at $296.11, down 0.39% today, with a bullish technical outlook supported by moving averages and a consensus price target of $305. The company reported $2.58B revenue in 2025 with net income of $759.90M, showing a significant turnaround from prior losses. Recent news highlights Nasdaq compliance restoration and participation in industry events, reinforcing operational stability.
BIO presents a positive investment case with strong analyst support (53.85% buy ratings) and improving profitability, though high P/E of 49.27 and recent earnings misses pose valuation and execution risks. Upside potential exists if the company meets future earnings expectations, but investors should monitor debt levels and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
